New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
07:23 EDTPTCTPTC Therapeutics: EMA adopted negative opinion on MAA for Atuluren approval
PTC Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on the company's marketing authorization application for conditional approval of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy. The response from the CHMP is consistent with the company's previous guidance concerning the substantial risks regarding conditional EMA approval and underscores the importance of PTC's work in completing the ongoing confirmatory Phase 3 clinical trial. In April 2013, PTC initiated a 48-week, 220-patient confirmatory Phase 3 clinical trial of ataluren for the treatment of nmDMD. The trial is on track to complete enrollment in mid-2014 with top-line data expected in mid-2015. PTC intends to request a re-examination of the CHMP opinion with a final outcome expected in the second quarter of 2014, when the confirmatory study is expected to be more fully enrolled.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
07:17 EDTPTCTPTC Therapeutics price tarrget raised to $55 from $40 at Credit Suisse
Subscribe for More Information
September 23, 2014
08:54 EDTPTCTPTC Therapeutics price target raised to $50 from $37 at BofA/Merrill
Subscribe for More Information
September 22, 2014
10:35 EDTPTCTPTC Therapeutics management to meet with Roth Capital
Subscribe for More Information
September 17, 2014
08:04 EDTPTCTPTC Therapeutics prepares launch of Translarna in Europe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use